September 26, 2019
Shionogi to Present New Data at IDWeek 2019
– Including Cefiderocol Phase III APEKS-NP Trial as Late-breaker Oral Presentation – OSAKA, Japan & FLORHAM PARK, N.J.–(BUSINESS WIRE)–Shionogi &…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Asia
September 26, 2019
Takeda presents efficacy for nacrolepsy type 1 Orexin receptor agonist TAK-925
Takeda’s presentation has shown TAK-925 was well tolerated in patients with narcolepsy type 1 and increased wakefulness compared to placebo.
September 25, 2019
Entyvio shows superiority over Humira in first head-to-head biologic study in ulcerative colitis
Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis
September 20, 2019
Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai get approval of Safinamide for Parkinson’s Disease in Japan
Italian biopharmaceutical specialist for nervous diseases solutions, Newron Pharmaceuticals, and it’s partners Meiji Seika Pharma together with Eisai, got approval to produce and sell Equifina tablets in Japan.
September 19, 2019
Takeda recognized in the 2019 Dow Jones Sustainability World Index
Takeda has been named in the Dow Jones Sustainabilitz World Index, having more than double the average overall industry score, the company said in a press release Wednesday, noting it was also named in Dow Jones Sustainability Asia Pacific Index for 10th Consecutive Year.
September 10, 2019
Daiichi Sankyo’s U3-1402 show reduction in tumor size in testing
Daiichi Sankyo’s test of HER3 antibody drug conjugate U3-1402 data suggest that targeting HER3 with may be an effective treatment strategy irrespective of mechanism of resistance identified in the setting of EGFR TKI resistance, where new precision treatments are needed, said Helena Yu, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, and a trial investigator.
September 10, 2019
Clover Biopharmaceuticals Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal Carcinomatosis
BEIJING–(BUSINESS WIRE)–Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient…
September 10, 2019
Covance Unveils New R&D Center in Shanghai
Inauguration Ceremony Highlights World-Class, Comprehensive Drug Development Capabilities and More Than Two Decades of Growth in China BURLINGTON, N.C.–(BUSINESS WIRE)–LabCorp®…
September 9, 2019
MicuRx Pharmaceuticals Reports Positive Top-Line Results From a US Phase 2 ABSSSI Clinical Trial of Novel Antibiotic Contezolid Acefosamil
FOSTER CITY, Calif. & SHANGHAI–(BUSINESS WIRE)–MicuRx Pharmaceuticals, Inc., today announced positive top-line results for study MRX4-201, a US Phase 2…
August 15, 2019
Trovagene with new data from testing onvansertib with Zytiga for certain prostate cancer
Trovagene will present new clinical data from its Phase 2 trial of onvansertib, in combination with Zytiga (abiraterone acetate)/prednisone, in…